First, we need to note that Tortoise releasing a record with anyone other than Thrill Jockey after a 30-plus-year ...
AI disruption and government stimulus could drive broadening economic growth. Click here to read more about the US economy.
Taken together, it’s likely that Netflix’s soaring valuation has already priced in outsized growth expectations stemming from ...
We reveal a trove of niche-ass protein snacks, including a Canadian sweet potato-based Orange Creamsicle bar, a beef tallow ...
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
Thanks to a huge battery upgrade and much better-than-expected sound, this may be the only SoundLink Micro speaker worth ...
New research on global compensation from Deel and Carta highlights the outsized influence of macro issues like AI and ...
In today’s CEO Daily: Diane Brady on Fortune’s 100 Best Companies to Work For in Europe. The big story: John Bolton indicted; ...
Case study: How Bournemouth University is building the next-generation of broadcast production teams
Bournemouth University’s Andrew Kitchenham reveals a fresh approach to teaching digital technologies in the university's ...
At this point last year, it was +12. Vanderbilt has the SEC’s top-ranked offense, while the defense has been more ...
The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results